Paula Munderi
Overview
Explore the profile of Paula Munderi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
2840
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bennedbaek M, Zhukova A, Tang M, Bennet J, Munderi P, Ruxrungtham K, et al.
Virus Evol
. 2021 Sep;
7(2):veab055.
PMID: 34532059
Understanding of pandemics depends on the characterization of pathogen collections from well-defined and demographically diverse cohorts. Since its emergence in Congo almost a century ago, Human Immunodeficiency Virus Type 1...
2.
Prendergast A, Szubert A, Pimundu G, Berejena C, Pala P, Shonhai A, et al.
AIDS
. 2021 Jul;
35(10):1537-1548.
PMID: 34270487
Objective: To determine the impact of virological control on inflammation and cluster of differentiation 4 depletion among HIV-infected children initiating antiretroviral therapy (ART) in sub-Saharan Africa. Design: Longitudinal cohort study....
3.
Kavishe B, Vanobberghen F, Katende D, Kapiga S, Munderi P, Baisley K, et al.
PLoS One
. 2019 Dec;
14(12):e0223189.
PMID: 31809516
Background: Dyslipidemia is a leading risk factor for atherosclerotic cardiovascular disease. There are few published epidemiological data regarding dyslipidemia in Africa. We determined full lipid and apolipoprotein profiles and investigated...
4.
Ross L, Walker A, Lou Y, Tenorio A, Gibb D, Double J, et al.
PLoS One
. 2019 Nov;
14(11):e0225199.
PMID: 31725787
A retrospective analysis of the randomized controlled DART (Development of AntiRetroviral Therapy in Africa; ISRCTN13968779) trial in HIV-1-positive adults initiating antiretroviral therapy with co-formulated zidovudine/lamivudine plus either tenofovir, abacavir, or...
5.
Kyosiimire-Lugemwa J, Anywaine Z, Abaasa A, Levin J, Gombe B, Musinguzi K, et al.
J Infect Dis
. 2019 Nov;
222(3):381-390.
PMID: 31714954
Background: Cotrimoxazole preventive therapy (CPT) in human immunodeficiency virus (HIV) infection is a World Health Organization-recommended standard of care in resource-limited settings, but the mechanism of CPT's beneficial effects is...
6.
Munderi P, Were E, Avihingsanon A, Mbida P, Mohapi L, Moussa S, et al.
South Afr J HIV Med
. 2019 Aug;
20(1):949.
PMID: 31392036
Background: In low- and middle-income countries (LMICs), a substantial unmet need for affordable single-tablet regimen (STR) options remains. Rilpivirine (RPV, TMC278) is formulated in a low-cost STR with tenofovir disoproxil...
7.
Nsanya M, Kavishe B, Katende D, Mosha N, Hansen C, Nsubuga R, et al.
J Clin Hypertens (Greenwich)
. 2019 Feb;
21(4):470-478.
PMID: 30811099
We conducted a cross-sectional study among school/college students in Tanzania and Uganda to determine the prevalence of high blood pressure (BP) and associated factors. Participants were classified to have high...
8.
Anywaine Z, Levin J, Kasirye R, Lutaakome J, Abaasa A, Nunn A, et al.
PLoS One
. 2019 Jan;
13(12):e0206907.
PMID: 30596666
Background: Cotrimoxazole (CTX) preventive therapy (CPT) reduces opportunistic infections and malaria in HIV-infected patients. In Africa, policies on sustained CPT during antiretroviral therapy (ART) differ between countries. We assessed the...
9.
Barre-Sinoussi F, Abdool Karim S, Albert J, Bekker L, Beyrer C, Cahn P, et al.
J Int AIDS Soc
. 2018 Jul;
21(7):e25161.
PMID: 30044059
Introduction: Globally, prosecutions for non-disclosure, exposure or transmission of HIV frequently relate to sexual activity, biting, or spitting. This includes instances in which no harm was intended, HIV transmission did...
10.
Baker J, Sharma S, Grund B, Rupert A, Metcalf J, Schechter M, et al.
Open Forum Infect Dis
. 2018 Jan;
4(4):ofx262.
PMID: 29308409
Background: The Strategic Timing of AntiRetroviral Treatment (START) trial demonstrated that immediate (at CD4+ >500 cells/µL) vs deferred (to CD4+ <350 cells/µL or AIDS) antiretroviral therapy (ART) initiation reduced risk...